Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s12032-017-0956-8.

Title:
Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo | Medical Oncology
Description:
Epithelial ovarian carcinoma is the most lethal of gynecologic malignancies. There is a need to optimize the currently available treatment strategies and to urgently develop novel therapeutic agents against chemotherapy-resistant disease. The objective of our study was to evaluate neratinib’s preclinical efficacy in treating HER2-amplified ovarian cancer. Neratinib’s efficacy in treating HER2-amplified ovarian cancer was studied in vitro utilizing six primary tumor cell lines with differential HER2/neu expression. Flow cytometry was utilized to assess IC50, cell signaling changes, and cell cycle distribution. Neratinib’s in vivo efficacy was evaluated in HER2-amplified epithelial ovarian carcinoma xenografts. Three of six (50%) ovarian cancer cell lines were HER2/neu-amplified. Neratinib showed significantly higher efficacy in treating HER2/neu-amplified cell lines when compared to the non-HER2/neu-amplified tumor cell lines (mean Ā± SEM IC50:0.010 Ī¼M Ā± 0.0003 vs. 0.076 Ī¼M Ā± 0.005 p < 0.0001). Neratinib treatment significantly decreased the phosphorylation of the transcription factor S6, leading to arrest of the cell cycle in G0/G1 phase. Neratinib prolonged survival in mice harboring HER2-amplified epithelial ovarian carcinoma xenografts (p = 0.003). Neratinib inhibits proliferation, signaling, cell cycle progression and tumor growth of HER2-amplified epithelial ovarian carcinoma in vitro. Neratinib inhibits xenograft growth and improves overall survival in HER2/neu-amplified ovarian cancer in vivo. Clinical trials are warranted.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Health & Fitness
  • Education
  • Science

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We don't see any clear sign of profit-making.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {šŸ”}

cancer, pubmed, article, google, scholar, cas, ovarian, breast, neratinib, carcinoma, treatment, epithelial, cell, central, oncol, bellone, efficacy, herneu, patients, vitro, santin, therapy, trastuzumab, vivo, receptor, serous, gynecol, herpositive, study, phase, growth, clin, res, english, human, uterine, trial, privacy, cookies, content, oncology, herneuamplified, lopez, heramplified, lines, factor, survival, mice, clinical, prognostic,

Topics {āœ’ļø}

biomarker triplet nampt/vegf/her2 her2/neu-amplified ovarian cancer month download article/chapter erbb family-targeted agents her2-positive breast cancer hr-/her2+ breast cancer university campus bio-medico differential her2/neu expression trastuzumab-based adjuvant therapy endometrial serous carcinoma u01 ca176067-01a1 grants her2/neu receptor de la garza-salazar ovarian carcinoma tissue her2/neu-amplified epithelial ovarian cancers her2-directed therapy anti-her2 therapy short-term survivors 2-positive breast cancer her2 amplified carcinosarcoma full article pdf metastatic breast cancer recurrent ovarian cancer early breast cancer clinical trials siegel er capecitabine combination therapy human breast cancer privacy choices/manage cookies ovarian carcinoma transcription factor s6 cell cycle progression related subjects c-erbb-2 oncoprotein her2 therapy 2/neu gene amplification g0/g1 phase breast cancer res standard her2 testing nat rev cancer cancer treat rev schwab cl targeted therapies somatic brca1/2 mutations human participants performed article menderes neratinib inhibits proliferation irreversible inhibitor ovarian cancer

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo
         description:Epithelial ovarian carcinoma is the most lethal of gynecologic malignancies. There is a need to optimize the currently available treatment strategies and to urgently develop novel therapeutic agents against chemotherapy-resistant disease. The objective of our study was to evaluate neratinib’s preclinical efficacy in treating HER2-amplified ovarian cancer. Neratinib’s efficacy in treating HER2-amplified ovarian cancer was studied in vitro utilizing six primary tumor cell lines with differential HER2/neu expression. Flow cytometry was utilized to assess IC50, cell signaling changes, and cell cycle distribution. Neratinib’s in vivo efficacy was evaluated in HER2-amplified epithelial ovarian carcinoma xenografts. Three of six (50%) ovarian cancer cell lines were HER2/neu-amplified. Neratinib showed significantly higher efficacy in treating HER2/neu-amplified cell lines when compared to the non-HER2/neu-amplified tumor cell lines (mean ± SEM IC50:0.010 μM ± 0.0003 vs. 0.076 μM ± 0.005 pĀ <Ā 0.0001). Neratinib treatment significantly decreased the phosphorylation of the transcription factor S6, leading to arrest of the cell cycle in G0/G1 phase. Neratinib prolonged survival in mice harboring HER2-amplified epithelial ovarian carcinoma xenografts (pĀ =Ā 0.003). Neratinib inhibits proliferation, signaling, cell cycle progression and tumor growth of HER2-amplified epithelial ovarian carcinoma in vitro. Neratinib inhibits xenograft growth and improves overall survival in HER2/neu-amplified ovarian cancer in vivo. Clinical trials are warranted.
         datePublished:2017-04-10T00:00:00Z
         dateModified:2017-04-10T00:00:00Z
         pageStart:1
         pageEnd:8
         sameAs:https://doi.org/10.1007/s12032-017-0956-8
         keywords:
            Neratinib
            Epithelial ovarian carcinoma
            SCID mice
            HER2/neu
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-017-0956-8/MediaObjects/12032_2017_956_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-017-0956-8/MediaObjects/12032_2017_956_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-017-0956-8/MediaObjects/12032_2017_956_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-017-0956-8/MediaObjects/12032_2017_956_Fig4_HTML.gif
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
               1357-0560
            volumeNumber:34
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gulden Menderes
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elena Bonazzoli
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stefania Bellone
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jonathan D. Black
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Salvatore Lopez
               affiliation:
                     name:University Campus Bio-Medico of Roma
                     address:
                        name:Division of Gynecologic Oncology, University Campus Bio-Medico of Roma, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Francesca Pettinella
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alice Masserdotti
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Luca Zammataro
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Babak Litkouhi
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elena Ratner
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dan-Arin Silasi
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Masoud Azodi
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter E. Schwartz
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alessandro D. Santin
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo
      description:Epithelial ovarian carcinoma is the most lethal of gynecologic malignancies. There is a need to optimize the currently available treatment strategies and to urgently develop novel therapeutic agents against chemotherapy-resistant disease. The objective of our study was to evaluate neratinib’s preclinical efficacy in treating HER2-amplified ovarian cancer. Neratinib’s efficacy in treating HER2-amplified ovarian cancer was studied in vitro utilizing six primary tumor cell lines with differential HER2/neu expression. Flow cytometry was utilized to assess IC50, cell signaling changes, and cell cycle distribution. Neratinib’s in vivo efficacy was evaluated in HER2-amplified epithelial ovarian carcinoma xenografts. Three of six (50%) ovarian cancer cell lines were HER2/neu-amplified. Neratinib showed significantly higher efficacy in treating HER2/neu-amplified cell lines when compared to the non-HER2/neu-amplified tumor cell lines (mean ± SEM IC50:0.010 μM ± 0.0003 vs. 0.076 μM ± 0.005 pĀ <Ā 0.0001). Neratinib treatment significantly decreased the phosphorylation of the transcription factor S6, leading to arrest of the cell cycle in G0/G1 phase. Neratinib prolonged survival in mice harboring HER2-amplified epithelial ovarian carcinoma xenografts (pĀ =Ā 0.003). Neratinib inhibits proliferation, signaling, cell cycle progression and tumor growth of HER2-amplified epithelial ovarian carcinoma in vitro. Neratinib inhibits xenograft growth and improves overall survival in HER2/neu-amplified ovarian cancer in vivo. Clinical trials are warranted.
      datePublished:2017-04-10T00:00:00Z
      dateModified:2017-04-10T00:00:00Z
      pageStart:1
      pageEnd:8
      sameAs:https://doi.org/10.1007/s12032-017-0956-8
      keywords:
         Neratinib
         Epithelial ovarian carcinoma
         SCID mice
         HER2/neu
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-017-0956-8/MediaObjects/12032_2017_956_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-017-0956-8/MediaObjects/12032_2017_956_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-017-0956-8/MediaObjects/12032_2017_956_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-017-0956-8/MediaObjects/12032_2017_956_Fig4_HTML.gif
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
            1357-0560
         volumeNumber:34
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gulden Menderes
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elena Bonazzoli
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stefania Bellone
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jonathan D. Black
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Salvatore Lopez
            affiliation:
                  name:University Campus Bio-Medico of Roma
                  address:
                     name:Division of Gynecologic Oncology, University Campus Bio-Medico of Roma, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Francesca Pettinella
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alice Masserdotti
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Luca Zammataro
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Babak Litkouhi
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elena Ratner
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dan-Arin Silasi
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Masoud Azodi
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter E. Schwartz
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alessandro D. Santin
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
         1357-0560
      volumeNumber:34
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:University Campus Bio-Medico of Roma
      address:
         name:Division of Gynecologic Oncology, University Campus Bio-Medico of Roma, Rome, Italy
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gulden Menderes
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Elena Bonazzoli
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Stefania Bellone
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Jonathan D. Black
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Salvatore Lopez
      affiliation:
            name:University Campus Bio-Medico of Roma
            address:
               name:Division of Gynecologic Oncology, University Campus Bio-Medico of Roma, Rome, Italy
               type:PostalAddress
            type:Organization
      name:Francesca Pettinella
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Alice Masserdotti
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Luca Zammataro
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Babak Litkouhi
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Elena Ratner
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Dan-Arin Silasi
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Masoud Azodi
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Peter E. Schwartz
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Alessandro D. Santin
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Division of Gynecologic Oncology, University Campus Bio-Medico of Roma, Rome, Italy
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
      name:Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {šŸ”—}(220)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

4.74s.